Ekso Bionics (NASDAQ:EKSO) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note released on Saturday morning. The firm issued a hold rating on the stock.

A number of other equities research analysts also recently issued reports on the company. Lake Street Capital started coverage on Ekso Bionics in a research report on Monday, June 24th. They set a buy rating and a $2.50 price target on the stock. HC Wainwright reaffirmed a buy rating and issued a $10.00 target price on shares of Ekso Bionics in a report on Tuesday, July 30th.

Ekso Bionics Stock Performance

Shares of Ekso Bionics stock opened at $1.15 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.42 and a quick ratio of 1.77. The stock’s 50-day moving average is $1.10 and its 200-day moving average is $1.28. The firm has a market cap of $20.90 million, a price-to-earnings ratio of -1.19 and a beta of 1.51. Ekso Bionics has a one year low of $0.62 and a one year high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings data on Monday, July 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Ekso Bionics had a negative net margin of 68.41% and a negative return on equity of 92.08%. The business had revenue of $4.95 million during the quarter, compared to the consensus estimate of $5.34 million. During the same quarter in the prior year, the company earned ($0.31) EPS. Equities analysts predict that Ekso Bionics will post -0.42 earnings per share for the current fiscal year.

Institutional Trading of Ekso Bionics

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC lifted its holdings in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 596,050 shares of the company’s stock after buying an additional 454,892 shares during the period. Kent Lake Capital LLC owned approximately 3.28% of Ekso Bionics worth $811,000 at the end of the most recent reporting period. Institutional investors own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.